FDA accepts NDAs for Gilead HIV therapies

The regulator accepts Gilead Sciences' (GILD) NDAs for cobicistat, a pharmacoenhancing agent that increases blood levels of protease inhibitors atazanavir and darunavir and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults.

After the company submitted its original NDAs in June 2012, the FDA issued CRLs stating it could not approve the products for commercial sale due to deficiencies in documentation and validation of certain quality testing procedures and methods that FDA inspectors observed on site.

The firm believes it has effectively addressed the agency's concerns.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs